Prophylix

Prophylix is a clinical-stage biotechnology company dedicated to developing the first prophylactic treatment for fetal and neonatal alloimmune thrombocytopenia (FNAIT). FNAIT is a rare but potentially devastating condition where a mother's immune system attacks the platelets of her fetus, leading to severe bleeding or intracranial hemorrhage. The company's lead product, NAITgam, is a hyperimmune globulin derived from the plasma of immunized women, designed to prevent the mother from becoming sensitized to fetal platelets. By providing a targeted preventative therapy, Prophylix aims to eliminate the risk of life-threatening bleeding in newborns and reduce the need for invasive fetal monitoring. The company operates primarily out of Norway and Denmark, leveraging specialized expertise in platelet immunology.